The genetic variability of therapy response was recently shown in several independent studies for the common drugs used for T2D treatment, including biguanides (metformin), DPP-4 inhibitors/GLP1R agonists and sulfonylureas/meglitinides. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.